A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas - PubMed
3 days ago
- #meta-analysis
- #B-cell-lymphoma
- #BTKi
- Meta-analysis compares efficacy of BTKi monotherapies (zanubrutinib, acalabrutinib, ibrutinib) in B cell lymphomas.
- Zanubrutinib shows statistically significant improvements in complete response (CR) and overall response rate (ORR) compared to acalabrutinib and ibrutinib.
- Pooled odds ratios (ORs) favor zanubrutinib in various B cell lymphoma indications, including R/R MCL and R/R MZL.
- Findings suggest zanubrutinib as the most effective BTKi treatment option across B cell lymphomas.
- Study based on existing clinical trials without new human or animal studies.